News Releases

Year

13 Nov '24

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Phase 3 NEAT clinical trial on track with 32 patients enrolled to date with majority of U.S. and European study sites now enrolling patients SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 13, 2024-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to

PDF Version

12 Nov '24

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 12, 2024-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the presentation of two posters at the 2024

PDF Version

11 Nov '24

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 11, 2024-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the poster presentation at the 53 rd Child

PDF Version

14 Oct '24

Quince Therapeutics to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 14, 2024-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that management will present at three upcoming

PDF Version

03 Sep '24

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 3, 2024-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that Dirk Thye , M.D., Quince’s Chief Executive

PDF Version

15 Aug '24

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Findings from largest completed study in A-T demonstrated favorable safety profile Study showed positive effect of EryDex treatment in a subset of patients with A-T ages six to nine – the age range that typically experiences rapid clinical decline Quince recently initiated pivotal Phase 3 NEAT

PDF Version

13 Aug '24

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Strong cash position expected to provide sufficient operating runway into 2026; Phase 3 topline results expected in the fourth quarter of 2025 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 13, 2024-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to

PDF Version

25 Jun '24

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 25, 2024-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today announced that the

PDF Version

03 Jun '24

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

Fast Track designation underscores the high unmet medical need, with currently no approved therapeutic treatments for the rare pediatric disease Ataxia-Telangiectasia SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 3, 2024-- Quince Therapeutics, Inc.

PDF Version

13 May '24

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 13, 2024-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today provided an update on

PDF Version

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 16